|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0278 - 0.0278|
|52 Week Range||0.0001 - 0.0800|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Blackhawk Growth Corp. (CSE: BLR; Franfurt:0JJ; US-OTC: BLRZF) (the “Corporation” or “Blackhawk”), is pleased to provide a corporate update on its latest investment NuWave Foods Inc. (“Nu Wave”). NuWave recently signed a “Technology Evaluation and License Option Agreement” (“TELOA”) with EnWave Corporation (“EnWave”) (ENW.V). During the term of the TELOA, NuWave will have full access to EnWave’s patented drying technology and access to their food engineers for product development and technology evaluation purposes.
In response to more politicians demanding increased testing and recent comments from Governor Andrew Cuomo of New York stating, “The more testing, the more open the economy”, Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ; US-OTC:BLRZF) (the “Corporation” or “Blackhawk”), is pleased to announce that it has signed a non-exclusive distribution agreement with a private arms-length California-based entity to distribute Innovita’s 2019-nCoV Ab testing kits used in the detection of antibodies associated with COVID-19. The distributor will be responsible for their own costs associated with the distribution of the test kits to healthcare clinics, government organizations, pharmacies and retailers in the US, and all profits will be divided evenly between Blackhawk and the distributor.
Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ; US-OTC:BLRZF) (the “Corporation” or “Blackhawk”), is pleased to announce that after submitting its initial order on May 1, 2020 for 1,000 Innovita manufactured COVID-19 antibody testing kits, the Company can confirm that the kits arrived and were delivered to the healthcare clinic in Rocklin, California on May 6, 2020. “This is the start we were hoping for,” said Frederick Pels, CEO of Blackhawk.